Results for tag: "DCVAC Pca"

DCVAC PCa is a type of cancer vaccine developed to treat prostate cancer. It is a personalized immunotherapy, meaning it is tailored to the individual patient's tumor. The vaccine is made from the patient's own tumor cells, which are modified to stimulate the patient's immune system to recognize and attack the cancer cells. DCVAC PCa is designed to be used in combination with other treatments, such as chemotherapy and radiation therapy. The DCVAC PCa market is a rapidly growing field of cancer immunotherapy. It is a promising treatment option for prostate cancer patients, as it has the potential to reduce the risk of recurrence and improve overall survival. Companies in the DCVAC PCa market include Immunovia AB, Oncovir, Inc., and ImmunoCellular Therapeutics, Ltd. Show Less Read more